Cell Medica: About

• Company overview
• Our team
  • Senior management
  • Board of directors
  • Scientific advisory board

Cell Medica's leadership team provides a combination of biotech, financial and start-up expertise to tackle the unusual challenges of building a profitable cell therapy business.

• 

  Nigel Burns

  Chairman

  Nigel was a member of the senior management team at Cambridge Antibody Technology and brings over 20 years experience in the biotech sector to Cell Medica. At CAT, he was responsible for strategic alliances and led negotiations of significant transactions with other pharmaceutical and biotech companies including the early discussions with Astra Zeneca, which acquired CAT in 2006. He also chaired CAT’s Product Steering Committee, responsible for product management strategy and pipeline. (BSc Biochemistry PhD, Imperial College).
• 

  Gregg Sando

  Chief Executive Officer

  Gregg Sando is the founder and CEO of Cell Medica. After a career in investment banking based both in London and New York, he completed his Immunology MSc degree at the medical school of Imperial College. Recognizing the significant progress taking place in the field of cellular immunotherapy, Gregg formed Cell Medica in cooperation with a small group of the leading clinicians and immunologists who were pioneering this new mode of medical treatment.
• 

  Maina Bhaman

  Director

  Maina is the Director of Heathcare Investments at Imperial Innovations. She has extensive start-up experience gained through working at biotechnology ventures for over ten years both in the UK and US. Previously Maina was a Senior Scientist at Celltech (formerly Oxford Glyco Sciences) where she was responsible for the successful management of several drug discovery projects. Her US experience includes Chimeric Therapies, a cell therapy start-up based in Philadelphia. (MBA Tanaka Business School; BSc University of Texas at Austin).
• 

  Thomas Hecht

  Director

  Thomas is an experienced biotechnology professional with a clinical background in haematology and internal medicine. He was a member of the team which helped build Amgen’s European operations where he held various executive positions including Vice President - Marketing for Hematology and Oncology. (MD, University of Freiburg).